Invasive fungal infections in solid organ transplant recipients

Clinical Microbiology and Infection

Volumn 20, Issue s7, 2014, Pages 27-48

  Gavalda J ^a   Meije, Y ^a   Fortun J ^b   Roilides, E ^c   Saliba, F ^d   Lortholary, O ^e   Munoz P ^f,g,h,i   Grossi, P ^j   Cuenca Estrella, M ^k  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d HÔPITAL PAUL BROUSSE   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ SCHOOL OF MEDICINE   (Spain)

^j UNIVERSITY OF INSUBRIA   (Italy)

^k INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Drug interactions; Invasive aspergillosis; Invasive candidiasis; Solid organ transplantation; Transplant infectious disease

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN A; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICAFUNGIN; NEVIRAPINE; PHENYTOIN; POSACONAZOLE; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ASPERGILLUS; CANDIDA; CANDIDEMIA; CLINICAL TRIAL (TOPIC); CRYPTOCOCCOSIS; FILAMENTOUS FUNGUS; GRAFT RECIPIENT; HEART GRAFT; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; KIDNEY TRANSPLANTATION; LIVER GRAFT; REVIEW; RISK ASSESSMENT; SYSTEMIC MYCOSIS; URINARY TRACT INFECTION; CANDIDIASIS, INVASIVE; IMMUNOCOMPROMISED PATIENT; INVASIVE PULMONARY ASPERGILLOSIS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION;

CANDIDIASIS, INVASIVE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INVASIVE PULMONARY ASPERGILLOSIS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; TRANSPLANT RECIPIENTS;

EID: 84908215762     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12660     Document Type: Review

References (176)

1. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-1111.
2. Rodriguez C, Munoz P, Rodriguez-Creixems M, Yanez JF, Palomo J, Bouza E. Bloodstream infections among heart transplant recipients. Transplantation 2006; 81: 384-391.
3. Moreno A, Cervera C, Gavalda J et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant 2007; 7: 2579-2586.
4. Albano L, Bretagne S, Mamzer-Bruneel MF et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis 2009; 48: 194-202.
5. Zicker M, Colombo AL, Ferraz-Neto BH, Camargo LF. Epidemiology of fungal infections in liver transplant recipients: a six-year study of a large Brazilian liver transplantation centre. Mem Inst Oswaldo Cruz 2011; 106: 339-345.
6. Puig-Asensio M, Padilla B, Garnacho-Montero J et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect 2014; 20: 245-254.
7. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 (suppl 1): 49-58.
8. Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46-52.
9. Gavalda J, Len O, San Juan R et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41: 52-59.
10. Lortholary O, Gangneux JP, Sitbon K et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011; 17: 1882-1889.
11. Munoz P, Ceron I, Valerio M et al. Invasive aspergillosis among heart transplant recipients: a 24-year perspective. J Heart Lung Transplant 2014; 33: 278-288.
12. Fortun J, Martin-Davila P, Moreno S et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8: 1065-1070.
13. Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am 2010; 24: 273-283.
14. Fortun J, Meije Y, Fresco G, Moreno S. Aspergillosis. Clinical forms and treatment. Enferm Infecc Microbiol Clin 2012; 30: 201-208.
15. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20: 1274-1281.
16. Munoz P, Rodriguez C, Bouza E et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004; 4: 636-643.
17. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1, 963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70: 112-116.
18. Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis 2009; 48: 1566-1576.
19. Bodro M, Sabe N, Gomila A et al. Risk factors, clinical characteristics, and outcomes of invasive fungal infections in solid organ transplant recipients. Transplant Proc 2012; 44: 2682-2685.
20. Singh N, Alexander BD, Lortholary O et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195: 756-764.
21. Datta K, Bartlett KH, Baer R et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis 2009; 15: 1185-1191.
22. Hagen F, Colom MF, Swinne D et al. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis 2012; 18: 1618-1624.
23. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010; 50: 291-322.
24. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7: 375-381.
25. Cuenca-Estrella M, Bernal-Martinez L, Isla G, Gomez-Lopez A, Alcazar-Fuoli L, Buitrago MJ. Incidence of zygomycosis in transplant recipients. Clin Microbiol Infect 2009; 15 (suppl 5): 37-40.
26. Neofytos D, Fishman JA, Horn D et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12: 220-229.
27. Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54: 1629-1636.
28. Singh N, Aguado JM, Bonatti H et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200: 1002-1011.
29. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6: 2365-2374.
30. Sun HY, Forrest G, Gupta KL et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation 2010; 90: 85-92.
31. Sole A, Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med 2009; 15: 243-253.
32. Cuenca-Estrella M, Verweij PE, Arendrup MC et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18 (suppl 7): 9-18.
33. Kasai M, Francesconi A, Petraitiene R et al. Use of quantitative real-time PCR to study the kinetics of extracellular DNA released from Candida albicans, with implications for diagnosis of invasive candidiasis. J Clin Microbiol 2006; 44: 143-150.
34. Nguyen MH, Wissel MC, Shields RK et al. Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012; 54: 1240-1248.
35. Sendid B, Caillot D, Baccouch-Humbert B et al. Contribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 2003; 41: 4551-4558.
36. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52: 750-770.
37. Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1→3)-β-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49: 1650-1659.
38. Held J, Kohlberger I, Rappold E, Busse Grawitz A, Hacker G. Comparison of (1→3)-β-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol 2013; 51: 1158-1164.
39. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
40. Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1, 3)β-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010; 48: 4083-4088.
41. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.
42. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1, 3-β-D-glucan assay reactivity. Clin Infect Dis 2008; 46: 1930-1931.
43. Leon C, Ruiz-Santana S, Saavedra P et al. Value of β-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 2012; 38: 1315-1325.
44. Avni T, Leibovici L, Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 2011; 49: 665-670.
45. Lau A, Halliday C, Chen SC, Playford EG, Stanley K, Sorrell TC. Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Microbiol 2010; 48: 811-816.
46. Fortun J, Meije Y, Buitrago M et al. Clinical Validation of Multiplex Quantitative Real-Time PCR (RT-PCR) for Invasive Candidiasis (IC) in Patients (pts) Admitted in Intensive Care Unit (ICU). Preliminary analysis. 23rd European Congress of Clinical Microbiology and Infectious Diseases; 2013; April 27-30; Berlin. Abstract # P1050.
47. Powell HL, Sand CA, Rennie RP. Evaluation of CHROMagar Candida for presumptive identification of clinically important Candida species. Diagn Microbiol Infect Dis 1998; 32: 201-204.
48. Wilson DA, Joyce MJ, Hall LS et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol 2005; 43: 2909-2912.
49. Hall L, Le Febre KM, Deml SM, Wohlfiel SL, Wengenack NL. Evaluation of the yeast traffic light PNA FISH probes for identification of Candida species from positive blood cultures. J Clin Microbiol 2012; 50: 1446-1448.
50. Spanu T, Posteraro B, Fiori B et al. Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol 2012; 50: 176-179.
51. Munoz P, Alcala L, Sanchez Conde M et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003; 75: 326-329.
52. Husain S, Mooney ML, Danziger-Isakov L et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant 2011; 30: 361-374.
53. Park YS, Seo JB, Lee YK et al. Radiological and clinical findings of pulmonary aspergillosis following solid organ transplant. Clin Radiol 2008; 63: 673-680.
54. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22: 258-266.
55. Cuenca-Estrella M, Bassetti M, Lass-Florl C, Racil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66 (suppl 1): 15-24.
56. Fortun J, Martin-Davila P, Alvarez ME et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001; 71: 145-149.
57. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-1427.
58. Aubry A, Porcher R, Bottero J et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with β-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44: 389-394.
59. Fortun J, Martin-Davila P, Alvarez ME et al. False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation 2009; 87: 256-260.
60. Kwak EJ, Husain S, Obman A et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42: 435-438.
61. Husain S, Paterson DL, Studer SM et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83: 1330-1336.
62. Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45: 1759-1765.
63. White PL, Mengoli C, Bretagne S et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol 2011; 49: 3842-3848.
64. Botterel F, Farrugia C, Ichai P, Costa JM, Saliba F, Bretagne S. Real-time PCR on the first galactomannan-positive serum sample for diagnosing invasive aspergillosis in liver transplant recipients. Transpl Infect Dis 2008; 10: 333-338.
65. Luong ML, Clancy CJ, Vadnerkar A et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52: 1218-1226.
66. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis: an analysis among 5, 521 consecutive organ transplant recipients. Transpl Infect Dis 2002; 4: 183-188.
67. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4: e21.
68. Singh N, Lortholary O, Dromer F et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation 2008; 86: 647-651.
69. Singh N, Alexander BD, Lortholary O et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46: e12-e18.
70. Singh N, Forrest G. Cryptococcosis in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): 192-198.
71. Grossi PA, Gasperina DD, Barchiesi F et al. Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. Transplant Proc 2011; 43: 2463-2471.
72. Ruiz-Camps I, Aguado JM, Almirante B et al. Guidelines for the prevention of invasive mould diseases caused by filamentous fungi by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Clin Microbiol Infect 2011; 17 (suppl 2): 1-24.
73. Guaraldi G, Cocchi S, Codeluppi M et al. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation 2005; 80: 1742-1748.
74. Gavalda J, Vidal E, Lumbreras C. Infection prevention in solid organ transplantation. Enferm Infecc Microbiol Clin 2012; 30 (suppl 2): 27-33.
75. Gavalda J, Meije Y, Len O, Pahissa A. Invasive fungal infection in solid organ transplant. Enferm Infecc Microbiol Clin 2012; 30: 645-653.
76. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71: 910-913.
77. Saliba F, Delvart V, Ichai P et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. Clin Transplant 2013; 27: E454-E461.
78. Aguado JM, Ruiz-Camps I, Munoz P et al. Guidelines for the treatment of invasive candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update. Enferm Infecc Microbiol Clin 2011; 29: 345-361.
79. Singhal S, Ellis RW, Jones SG et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl 2000; 6: 588-595.
80. Castroagudin JF, Ponton C, Bustamante M et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 2005; 37: 3965-3967.
81. Reed A, Herndon JB, Ersoz N et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 2007; 13: 1743-1750.
82. Hadley S, Huckabee C, Pappas PG et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11: 40-48.
83. Fortun J, Martin-Davila P, Moreno S et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813-819.
84. Aguado JM, Varo E, Usetti P et al. Safety of anidulafungin in solid organ transplant recipients. Liver Transpl 2012; 18: 680-685.
85. Fortun J, Martin-Davila P, Montejo M et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009; 87: 424-435.
86. Sun HY, Cacciarelli TV, Singh N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation 2013; 96: 573-578.
87. Saliba F, Fischer L, Pascher A et al. Micafungin as antifungal prophylaxis in high-risk liver transplantation: randomised multicentre trial. 16th Congress of the European Society for Organ Transplantation; 2013; September 8-11; Vienna. Abstract # P217.
88. Saliba F, Fischer L, Pascher A et al. Efficacy and safety of micafungin as antifungal prophylaxis in high-risk liver transplantation. 53rd International Congress on Antimicrobial Agents and Chemotherapy (ICAAC); 2013; September 10-13; Denver. Abstract # T810.
89. Pappas PG, Andes D, Schuster M et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006; 6: 386-391.
90. San-Juan R, Aguado JM, Lumbreras C et al. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation 2011; 92: 346-350.
91. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004; 39 (suppl 4): 200-206.
92. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12: 850-858.
93. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis 2006; 8: 213-218.
94. Palmer SM, Drew RH, Whitehouse JD et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545-548.
95. Drew RH, Dodds Ashley E, Benjamin DK, Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232-237.
96. Monforte V, Ussetti P, Gavalda J et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29: 523-530.
97. Gavalda J, Martin MT, Lopez P et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 2005; 49: 3028-3030.
98. Monforte V, Lopez-Sanchez A, Zurbano F et al. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J Heart Lung Transplant 2013; 32: 313-319.
99. Borro JM, Sole A, de la Torre M et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40: 3090-3093.
100. Monforte V, Ussetti P, Lopez R et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28: 170-175.
101. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75: 1571-1574.
102. Husain S, Paterson DL, Studer S et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008-3016.
103. Luong ML, Hosseini-Moghaddam SM, Singer LG et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant 2012; 12: 1929-1935.
104. Cadena J, Levine DJ, Angel LF et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9: 2085-2091.
105. Vadnerkar A, Nguyen MH, Mitsani D et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29: 1240-1244.
106. Singer JP, Boker A, Metchnikoff C et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31: 694-699.
107. Zwald FO, Spratt M, Lemos BD et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38: 1369-1374.
108. Epaulard O, Villier C, Ravaud P et al. A Multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French Nationwide Study. Clin Infect Dis 2013; 57: 182-188.
109. Pappas PG, Silveira FP. Candida in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): 173-179.
110. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
111. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-893.
112. Cornely OA, Bassetti M, Calandra T et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 (suppl 7): 19-37.
113. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
114. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527.
115. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51: 295-303.
116. Liu CY, Huang LJ, Wang WS et al. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect 2009; 58: 154-160.
117. Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine (Baltimore) 2011; 90: 237-249.
118. Boland JM, Chung HH, Robberts FJ et al. Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis. Mycoses 2011; 54: 354-360.
119. Kleinberg M. Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Med Mycol 2005; 43 (suppl 1): 289-294.
120. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
121. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
122. Fortun J, Martin-Davila P, Sanchez MA et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22: 408-413.
123. Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. J Heart Lung Transplant 2005; 24: 102-104.
124. Veroux M, Corona D, Gagliano M et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc 2007; 39: 1838-1840.
125. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-2645.
126. Groetzner J, Kaczmarek I, Wittwer T et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008; 27: 1-6.
127. Maertens J, Egerer G, Shin WS et al. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry. BMC Infect Dis 2010; 10: 182.
128. Winkler M, Pratschke J, Schulz U et al. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study. Transpl Infect Dis 2010; 12: 230-237.
129. Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
130. Alexander BD, Perfect JR, Daly JS et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008; 86: 791-796.
131. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-349.
132. Wadi J, Al-kawasmeh SI, Kamel MT, AlJayyousi BB. Disseminated invasive aspergillosis successfully treated with micafungin in a renal transplant recipient. Saudi J Kidney Dis Transpl 2010; 21: 914-918.
133. Fortun J, Carratala J, Gavalda J et al. Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update. Enferm Infecc Microbiol Clin 2011; 29: 435-454.
134. Mouas H, Lutsar I, Dupont B et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005; 40: 1141-1147.
135. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
136. Feist A, Lee R, Osborne S, Lane J, Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012; 31: 1177-1181.
137. Singh N, Lortholary O, Alexander BD et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005; 80: 1033-1039.
138. Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005; 40(suppl 6): 409-413.
139. Barrett JP, Vardulaki KA, Conlon C et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295-1320.
140. Sun HY, Alexander BD, Lortholary O et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009; 49: 1721-1728.
141. Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764-1767.
142. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
143. Day JN, Chau TT, Wolbers M et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013; 368: 1291-1302.
144. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 2008; 3: e2870.
145. Singh N, Lortholary O, Alexander BD et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005; 40: 1756-1761.
146. Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1991; 35: 726-729.
147. Bava AJ, Negroni R. Flucytosine + fluconazole association in the treatment of a murine experimental model of cryptococcosis. Rev Inst Med Trop Sao Paulo 1994; 36: 551-554.
148. Chin T, Fong IW, Vandenbroucke A. Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis. Pharmacotherapy 1990; 10: 305-307.
149. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45: 1610-1617.
150. Bandettini R, Castagnola E, Calvillo M et al. Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant. J Chemother 2009; 21: 108-109.
151. Bicanic T, Brouwer AE, Meintjes G et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009; 23: 701-706.
152. Liliang PC, Liang CL, Chang WN, Lu K, Lu CH. Use of ventriculoperitoneal shunts to treat uncontrollable intracranial hypertension in patients who have cryptococcal meningitis without hydrocephalus. Clin Infect Dis 2002; 34: E64-E68.
153. Graybill JR, Sobel J, Saag M et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30: 47-54.
154. Singh N, Lortholary O, Alexander BD et al. Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. Transplantation 2005; 80: 1131-1133.
155. Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, Heitman J. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743, 873) with calcineurin inhibitors FK506 and L-685, 818 against Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 739-746.
156. Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005; 40: 477-479.
157. Lanternier F, Chandesris MO, Poiree S et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 7: 2826-2828.
158. Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-133.
159. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50: 3968-3969.
160. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-371.
161. Lanternier F, Poiree S, Elie C et al. Pilot Prospective Study of High Dose (10 mg/kg/d) Liposomal Amphotericin B (L-AmB) for the Initial Treatment of Mucormycosis: AMBIZYGO Trial. 52nd International Congress on Antimicrobial Agents and Chemotherapy (ICAAC); 2012; September 9-12; San Francisco. Abstract # M1707.
162. Barchiesi F, Spreghini E, Santinelli A et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007; 51: 73-77.
163. Ibrahim AS, Gebremariam T, Luo G et al. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother 2011; 55: 1768-1770.
164. Spellberg B, Ibrahim AS, Chin-Hong PV et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67: 715-722.
165. Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743-1750.
166. Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47: 359-370.
167. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22: 111-113.
168. Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54: 4446-4450.
169. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
170. Nucci M, Marr KA, Vehreschild MJ et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect 2013; doi: 10.1111/1469-0691.
171. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744.
172. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc 2004; 36: 2708-2709.
173. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27: 825-834.
174. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
175. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42: 1171-1178.
176. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227-233.